The incidence of inhibitors in hemophilia A and the induction of immune tolerance

Advances in Experimental Medicine and Biology

Volumn 489, Issue , 2001, Pages 89-97

  Briet E ^a   Peters, M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR; CYCLOPHOSPHAMIDE; PREDNISONE; RECOMBINANT BLOOD CLOTTING FACTOR 8;

CONFERENCE PAPER; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HEMOPHILIA A; IMMUNE RESPONSE; IMMUNE RESPONSE GENE; IMMUNOLOGICAL TOLERANCE; INCIDENCE; PRIORITY JOURNAL; RISK FACTOR;

EID: 0035029304     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-1277-6_8     Document Type: Conference Paper

References (26)

1. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: Improved specificity and reliability
2. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada
3. A more uniformed measurement of factor VIII inhibitors
4. Southwestern Internal Medicine Conference: Shiga-like toxins in hemolyticuremic syndrome and thrombotic thrombocytopenic purpura
5. Factor VIII inhibitors in mild and moderate-severity haemophilia A
6. Haemophilia A: Mutation type determines risk of inhibitor formation
7. Heterogeneity of haemophilia A: A study with three different antisera
8. HLA class II profile: A weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO inhibitor working party
9. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII
10. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate
11. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands
12. The natural history of factor VIII:C inhibitors in patients with hemophilia A: A national comparative study. II. Observations on the initial development of factor VIII:C inhibitors
13. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate
14. Clinical course of factor VIII inhibitors developed after exposure to a pasteurised Dutch concentrate compared to classic inhibitors in hemophilia A
15. Incidence of factor VIII inhibitor development in severe hemophilia A patients treated only with one brand of highly purified plasma-derived concentrate
16. Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a single intermediate purity factor VIII product
17. How do some haemophiliacs develop inhibitors?
18. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A - Safety, efficacy, and development of inhibitors
19. A multicenter study of recombinant factor VIII (Recombinate): Safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A
20. High titer inhibitors in severe haemophilia A. A metaanalysis based on eight long-term follow-up studies concerning inhibitors associated with crude or intermediate purity factor VIII products
21. Immune tolerance for the treatment of factor VIII inhibitors - Twenty years' 'bonn protocol'
22. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide and factor VIII
23. Immune tolerance therapy for haemophilia A patients with acquired factor VIII alloantibodies: Comprehensive analysis of experience at a single institution
24. Induction of immune tolerance to factor VIII in hemophiliacs with inhibitors
25. Immune tolerance induction with once weekly factor VIII infusions in patients with hemophilia A and inhibitors
26. Low-dose immune tolerance induction in hemophilia A patients with inhibitors